Audited financials for Q and Year ended 31.03.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sandu Pharmaceuticals reported standalone audited results for Q4 and full year FY26 ended March 31, 2026. Revenue from operations grew by approximately 20% to Rs 1,68,534 (lakhs) for Q4 compared to Rs 93,459 (lakhs) in Q4 FY25. For the full year, revenue stood at Rs 1,40,693 (lakhs). Profit after tax for Q4 was Rs 17,651 (lakhs), a significant jump from Rs 9,751 (lakhs) in the corresponding period last year, representing PAT growth exceeding 60%. The company recommended a final dividend of Rs 1 per equity share (10% on face value of Rs 10). Auditors issued an unmodified opinion with no qualifications. Cash and cash equivalents improved substantially to Rs 590.7 (lakhs) from Rs 130.39 (lakhs) in the prior year.
Positive signal for shareholders with strong revenue growth (~20%) and robust PAT growth (~60%+). The company remains cash-generative with improved liquidity. Clean audit with unmodified opinion indicates financial transparency. The dividend declaration is a positive signal for investor returns.